PHAXIAM Therapeutics S.A.
PHAXIAM Therapeutics S.A., a clinical-stage biopharmaceutical company, focuses on developing bacteriophage-based therapies for severe resistance infections in France. The company develops and commercializes red cell-based therapies for cancers and orphan diseases. It develops anti-infectious therapies based on the use of bacteriophages (phages) to treat infections caused by Escherichia coli (E.co… Read more
Market Cap & Net Worth: PHAXIAM Therapeutics S.A. (PHXM)
PHAXIAM Therapeutics S.A. (PA:PHXM) has a market capitalization of $1.04 Million (€1.01 Million) as of March 18, 2026. Listed on the PA stock exchange, this France-based company holds position #37039 globally and #458 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHAXIAM Therapeutics S.A.'s stock price €0.10 by its total outstanding shares 10050400 (10.05 Million).
PHAXIAM Therapeutics S.A. Market Cap History: 2015 to 2025
PHAXIAM Therapeutics S.A.'s market capitalization history from 2015 to 2025. Data shows change from $2.44 Billion to $1.04 Million (-54.94% CAGR).
Index Memberships
PHAXIAM Therapeutics S.A. is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$48.16 Billion | 0.00% | #71 of 119 |
|
CAC Small90
CACS
|
$12.14 Billion | 0.01% | #47 of 64 |
|
CAC All-Tradable
CACT
|
$487.04 Billion | 0.00% | #85 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$487.04 Billion | 0.00% | #85 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$487.04 Billion | 0.00% | #85 of 179 |
|
CAC Health Care
FRHC
|
$70.93 Billion | 0.00% | #23 of 36 |
Weight: PHAXIAM Therapeutics S.A.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PHAXIAM Therapeutics S.A. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHAXIAM Therapeutics S.A.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
33.08x
PHAXIAM Therapeutics S.A.'s market cap is 33.08 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.44 Billion | $2.93 Million | -$15.01 Million | 834.02x | N/A |
| 2016 | $1.31 Billion | $4.14 Million | -$22.01 Million | 316.60x | N/A |
| 2017 | $1.76 Billion | $3.36 Million | -$33.53 Million | 524.36x | N/A |
| 2018 | $595.93 Million | $4.45 Million | -$38.22 Million | 134.01x | N/A |
| 2019 | $638.84 Million | $5.28 Million | -$62.66 Million | 120.92x | N/A |
| 2020 | $677.93 Million | $3.72 Million | -$73.30 Million | 182.34x | N/A |
| 2021 | $202.14 Million | $4.18 Million | -$53.80 Million | 48.36x | N/A |
| 2022 | $34.97 Million | $6.65 Million | -$228.00K | 5.26x | N/A |
| 2023 | $43.86 Million | $1.33 Million | -$23.49 Million | 33.08x | N/A |
Competitor Companies of PHXM by Market Capitalization
Companies near PHAXIAM Therapeutics S.A. in the global market cap rankings as of March 18, 2026.
Key companies related to PHAXIAM Therapeutics S.A. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PHAXIAM Therapeutics S.A. Historical Marketcap From 2015 to 2025
Between 2015 and today, PHAXIAM Therapeutics S.A.'s market cap moved from $2.44 Billion to $ 1.04 Million, with a yearly change of -54.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €1.04 Million | -94.05% |
| 2024 | €17.43 Million | -60.25% |
| 2023 | €43.86 Million | +25.41% |
| 2022 | €34.97 Million | -82.70% |
| 2021 | €202.14 Million | -70.18% |
| 2020 | €677.93 Million | +6.12% |
| 2019 | €638.84 Million | +7.20% |
| 2018 | €595.93 Million | -66.22% |
| 2017 | €1.76 Billion | +34.64% |
| 2016 | €1.31 Billion | -46.37% |
| 2015 | €2.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PHAXIAM Therapeutics S.A. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.04 Million USD |
| MoneyControl | $1.04 Million USD |
| MarketWatch | $1.04 Million USD |
| marketcap.company | $1.04 Million USD |
| Reuters | $1.04 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.